Additionally, the patients recruited for this study exhibited comorbidities associated with plasma YKL-40 levels as follows: asthma (n = 3), diabetes (n = 2), cardiovascular diseases (n = 2), chronic obstructive pulmonary disease (n = 2), and rheumatic diseases (n = 8). This evidence concerns the gene CHI3L1 and rheumatic disorder.